Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Kronos Bio Inc (KRON)

Kronos Bio Inc (KRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Kronos Bio Announces Leadership Change with Deborah Knobelman Appointed as President and Interim CEO

Kronos Bio appoints Deborah Knobelman as President and Interim CEO, succeeding Norbert Bischofberger amidst significant workforce reduction.Quiver AI SummaryKronos Bio, Inc. announced that Dr. Deborah...

KRON : 0.9579 (+3.21%)
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up

The company said this move is part of a broader strategy to implement cost-cutting measures.

IWC : 129.75 (+1.54%)
KRON : 0.9579 (+3.21%)
VXF : 192.94 (+1.36%)
VTI : 293.28 (+1.14%)
Kronos Bio Announces CEO Transition and Reduction in Force

KRON : 0.9579 (+3.21%)
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

KRON : 0.9579 (+3.21%)
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

KRON : 0.9579 (+3.21%)
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

KRON : 0.9579 (+3.21%)
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

KRON : 0.9579 (+3.21%)
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

KRON : 0.9579 (+3.21%)
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

KRON : 0.9579 (+3.21%)
5 Microcap Stocks With 65% or More Upside Potential

While they do carry higher-than-average risk, these microcaps also offer major upside potential for investors seeking startup-sized returns.

BTBT : 3.35 (-1.18%)
^BTCUSD : 95,462.38 (-1.20%)
ERJ24 : 3,144.04s (-0.63%)
GOEV : 0.0856 (-9.23%)
KRON : 0.9579 (+3.21%)
OGI : 1.5600 (+6.85%)
QBTS : 6.44 (+1.10%)

Barchart Exclusives

Elon Musk Didn't Expect Tesla or SpaceX to be Succesful, But He Did It Because They "Were Important Enough to do Anyway"
In a reflection on his entrepreneurial journey, tech magnate Elon Musk offered a glimpse into the mindset that led him to launch two of the world’s most groundbreaking ventures: Tesla and SpaceX. Speaking on his early years of founding these companies, Musk said, “I always have optimism, but I’m realistic.... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar